Akesis Pharmaceuticals

What Akesis Pharmaceuticals does

Akesiss Pharma Pvt. Ltd, operating under the trade name Akesis Pharmaceuticals, is a privately held Indian branded-generic pharmaceutical company founded in 2009 by Ashok Kumar K and headquartered in Kochi, Kerala. The company manufactures and markets 125+ branded generic formulations spanning 15+ therapeutic segments — including cardiology, endocrinology/diabetology, obstetrics and gynecology, orthopedics, urology, pulmonology, nutraceuticals, and critical care — organized into six specialty-focused divisions (Zalvo, Zalvo Life, Glyvo, Glyvo Life, Lazo, and Critical Care), each with dedicated sales and marketing directors targeting specialist physicians.

Its product portfolio spans oral solids, injectables, and topical preparations covering anti-hypertensives, anti-diabetics, lipid-lowering agents, anti-osteoarthritic and anti-osteoporotic drugs, antibiotic injectables (including carbapenems and anti-pseudomonal agents), gynecological and pregnancy supplements, infertility treatments, and respiratory drugs. Manufacturing is handled entirely by group affiliate Megasys Biotek Pvt Ltd at a GMP-compliant facility in the Kinfra Koratty Industrial Area, Thrissur, Kerala, under a fully integrated model from formulation development through processing and marketing.

The company operates a field-sales-led go-to-market model targeting doctors, specialists, hospitals, and pharmacies across India, supported by branch offices in Bangalore and Chennai and US representation through an NRI associate. Revenue is generated from one-time sales of branded generic formulations at price points governed by India's Drug Price Control Orders, with affordability positioned as a core value proposition. The company is part of the Akesiss Group of companies, employs 501–1,000 people, and maintains an ISO-defined quality management system; no public funding rounds, M&A, or revenue disclosures have been recorded.

Name

Akesis Pharmaceuticals

Legal name

Akesiss Pharma Pvt. Ltd

Website

https://akesiss.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Akesiss Pharma is a privately held Indian branded-generic pharmaceutical company founded in 2009, marketing 125+ formulations across 15+ therapeutic areas via six specialty divisions to specialist physicians, hospitals, and pharmacies across India, with manufacturing through group affiliate Megasys Biotek.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Branded generic medicines
• Pharmaceutical formulations
• Cardio-diabetology medications
• Critical care injectables
• Gynecology pharmaceuticals

Headquarters

HQ city

Kochi

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Personnel, Supply Chain, Operations, Technology or R&D

Revenue model

1. Branded Generic Pharmaceutical Sales: Akesiss Pharma generates revenue through the sale of branded generic pharmaceutical formulations across multiple therapeutic segments. The company operates with six specialty divisions covering cardiology, diabetology, gynecology, orthopedics, pulmonology, and critical care. Products are sold across India through a field sales organization targeting doctors, hospitals, and pharmacies. The company also organizes medical camps, educational programmes, and scientific updates as part of its healthcare engagement model.
2. International Market Expansion: The Managing Director's message references India emerging as a global pharmaceutical hub and Akesiss's plans to leverage this opportunity for growth in both domestic and global markets, suggesting future international revenue streams.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Akesiss Pharma develops, manufactures, and markets branded generic pharmaceutical formulations across multiple therapeutic segments including cardiology, diabetology, obstetrics & gynecology, orthopedics, pulmonology, and critical care. The company operates six specialty-focused divisions (Zalvo, Zalvo Life, Glyvo, Glyvo Life, Lazo, and Critical Care), with manufacturing handled by group entity Megasys Biotek Pvt Ltd at a GMP-compliant facility in Kerala. Its portfolio spans over 125 branded products across 15+ therapeutic categories, sold to doctors, hospitals, and pharmacies across India.

Product overview

Akesis Pharmaceuticals operates a multi-brand, multi-division pharmaceutical portfolio with six specialty-focused divisions: Glyvo and Glyvo Life (Cardio-Diabetology), Zalvo and Zalvo Life (Gynecology/General Medicine/Urology), Lazo (Orthopedics), and Critical Care (Injectables/Surgical). With over 125 brands across 15+ therapeutic segments including Cardiology, Endocrinology, Obstetrics & Gynecology, Orthopedics, Pulmonology, and critical care, the company offers branded generic formulations spanning anti-hypertensives, anti-diabetics, lipid-lowering drugs, anti-osteoarthritis medications, antibiotic injectables, and nutraceuticals. The divisions operate as distinct therapeutic units with specialized sales and marketing teams targeting specific medical specialties.

Differentiator

Problem solved

Functional benefit

Brands

• Zalvo: Gynecology and General Medicine division of Akesiss Pharma.
• Zalvo Life
• Glyvo
• Glyvo Life
• Lazo
• Critical Care

Products and services

• Glyvo Division Specialty product line targeting cardio-diabetology therapy areas, providing branded generic anti-diabetics and lipid-lowering drugs for endocrinologists, diabetologists, and physicians managing metabolic disorders.
• Glyvo Life Division Specialty product line targeting cardiovascular and metabolic health, including anti-hypertensives, cardiac supplements, and lipid-lowering drugs for cardiologists and general physicians.
• Zalvo Division Specialty product line covering women's health, pregnancy care, infertility management, and urology for gynecologists, obstetricians, and urologists.
• Zalvo Life Division Specialty product line targeting women's reproductive lifecycle and respiratory care, including pregnancy supplements, infertility treatments, and pulmonology medications.
• Lazo Division Specialty product line targeting bone and joint health, pain management, and gout treatment for orthopedic specialists and general practitioners.
• Critical Care Division Specialty product line targeting hospital and surgical settings with injectable antibiotics, hematinics, and anti-ulcerants for critical care specialists and hospital procurement.
• Nactylin ET N-Acetylcysteine 600mg effervescent tablet for bronchial asthma and COPD management with mucolytic and antioxidant action.
• Febufix Febuxostat 40mg tablet, a xanthine oxidase inhibitor for managing hyperuricemia in gout patients.
• Clenol Forte Combination vaginal suppository (Clindamycin, Clotrimazole, Tinidazole) for treatment of vulvo-vaginal infections.
• Colistimax Colistimethate Sodium 10,00,000 IU injection for serious gram-negative bacterial infections including Pseudomonas aeruginosa lung infections in cystic fibrosis.

Quantifiable outcome

• Over 125 branded generic formulations across 15+ therapeutic segments with significant market presence in cardiology, endocrinology, obstetrics & gynecology, orthopedics, pulmonology, and critical care.
• +2 more outcomes

Named customers4 records

Segments8 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Megasys Biotek Pvt LtdcoreTechnology or IntegrationMegasys Biotek Pvt Ltd is the group's fully integrated manufacturing facility located at Kinfra Koratty Industrial Area, Thrissur, Kerala. It handles all manufacturing operations for Akesiss Pharma's product portfolio of 125+ branded generics across 15+ therapeutic segments. The manufacturing unit is GMP-compliant and produces a wide range of pharmaceutical formulations including tablets, capsules, injectables, and topical preparations.

Scale indicators5 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• Mankind Pharma: One of India's largest branded-generic pharma companies with broad therapeutic coverage and a heavy field-force model. Highly comparable to Akesiss in target customers (doctors/specialists) and branded-generic GTM across cardio-diabetology and other chronic areas.
• Alkem Laboratories: Indian branded-generic pharma with strong presence in anti-infectives, gastroenterology, and chronic therapies. Directly comparable on therapeutic overlap (antibiotic injectables, anti-diabetics) and India-focused field sales model.
• Ajanta Pharma: Mid-sized Indian pharma specializing in branded generics across cardiology, diabetology, and specialty segments. Closely comparable to Akesiss in therapeutic focus and emerging-market distribution.
• Torrent Pharmaceuticals: Indian pharma with deep branded-generic presence in cardio-diabetology, gynecology, and orthopedics — directly overlapping Akesiss's six division structure and therapy mix.
• Ipca Laboratories: Indian branded-generic and API manufacturer with strong anti-malarial, anti-infective, and chronic-disease portfolios. Comparable on therapeutic breadth and India domestic field-sales focus.
• Glenmark Pharmaceuticals: India-headquartered pharma with branded-generic and specialty franchises including cardio-diabetology and gynecology. Directly comparable; notably, Akesiss director Thomsan George previously worked at Glenmark.
• Eris Lifesciences: Indian chronic-disease specialist pharma focused on cardio-diabetology and gynecology through a field-force-led model. Closely comparable to Akesiss's Glyvo/Glyvo Life and Zalvo divisions.
• J.B. Chemicals & Pharmaceuticals: Mid-sized Indian pharma with branded generics in cardiology, anti-infectives, and gynecology. Comparable on portfolio breadth, India field-sales model, and chronic-disease emphasis.
• Unichem Laboratories: Indian branded-generic company with presence in cardiology, neurology, and anti-infectives. Comparable in scale, product mix, and India-centric go-to-market.

Broad incumbents

• Cadila Healthcare (Zydus): One of India's largest pharma groups with deep branded-generic, API, and biosimilar portfolios across all of Akesiss's therapy areas. Larger and more diversified incumbent with overlapping specialty coverage.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/akesiss-pharma-private-limited-346490978828682
• Xx.com/akesiss_pharma
• LinkedInlinkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fakesiss.com%2F&title=Akesiss%20Pharma%20Pvt.%20Ltd&summary=&source=Akesiss%20Pharma%20Pvt.%20Ltd
• Pinterestpinterest.com/pin/create/button

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akesis Pharmaceuticals